Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2017

Open Access 01-12-2017 | Research

Caffeine modulates glucocorticoid-induced expression of CTGF in lung epithelial cells and fibroblasts

Authors: Markus Fehrholz, Kirsten Glaser, Christian P. Speer, Silvia Seidenspinner, Barbara Ottensmeier, Steffen Kunzmann

Published in: Respiratory Research | Issue 1/2017

Login to get access

Abstract

Background

Although caffeine and glucocorticoids are frequently used to treat chronic lung disease in preterm neonates, potential interactions are largely unknown. While anti-inflammatory effects of glucocorticoids are well defined, their impact on airway remodeling is less characterized. Caffeine has been ascribed to positive effects on airway inflammation as well as remodeling. Connective tissue growth factor (CTGF, CCN2) plays a key role in airway remodeling and has been implicated in the pathogenesis of chronic lung diseases such as bronchopulmonary dysplasia (BPD) in preterm infants. The current study addressed the impact of glucocorticoids on the regulation of CTGF in the presence of caffeine using human lung epithelial and fibroblast cells.

Methods

The human airway epithelial cell line H441 and the fetal lung fibroblast strain IMR-90 were exposed to different glucocorticoids (dexamethasone, budesonide, betamethasone, prednisolone, hydrocortisone) and caffeine. mRNA and protein expression of CTGF, TGF-β1-3, and TNF-α were determined by means of quantitative real-time PCR and immunoblotting. H441 cells were additionally treated with cAMP, the adenylyl cyclase activator forskolin, and the selective phosphodiesterase (PDE)-4 inhibitor cilomilast to mimic caffeine-mediated PDE inhibition.

Results

Treatment with different glucocorticoids (1 μM) significantly increased CTGF mRNA levels in H441 (p < 0.0001) and IMR-90 cells (p < 0.01). Upon simultaneous exposure to caffeine (10 mM), both glucocorticoid-induced mRNA and protein expression were significantly reduced in IMR-90 cells (p < 0.0001). Of note, 24 h exposure to caffeine alone significantly suppressed basal expression of CTGF mRNA and protein in IMR-90 cells. Caffeine-induced reduction of CTGF mRNA expression seemed to be independent of cAMP levels, adenylyl cyclase activation, or PDE-4 inhibition. While dexamethasone or caffeine treatment did not affect TGF-β1 mRNA in H441 cells, increased expression of TGF-β2 and TGF-β3 mRNA was detected upon exposure to dexamethasone or dexamethasone and caffeine, respectively. Moreover, caffeine increased TNF-α mRNA in H441 cells (6.5 ± 2.2-fold, p < 0.05) which has been described as potent inhibitor of CTGF expression.

Conclusions

In addition to well-known anti-inflammatory features, glucocorticoids may have adverse effects on long-term remodeling by TGF-β1-independent induction of CTGF in lung cells. Simultaneous treatment with caffeine may attenuate glucocorticoid-induced expression of CTGF, thereby promoting restoration of lung homeostasis.
Literature
1.
2.
Ryan RM, Ahmed Q, Lakshminrusimha S. Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia. Clin Rev Allergy Immunol. 2008;34:174–90.CrossRefPubMed
3.
Balany J, Bhandari V. Understanding the Impact of Infection, Inflammation, and Their Persistence in the Pathogenesis of Bronchopulmonary Dysplasia. Front Med. 2015;2:90.
4.
Speer CP. Inflammation and bronchopulmonary dysplasia: a continuing story. Semin Fetal Neonatal Med. 2006;11:354–62.CrossRefPubMed
5.
Thomas W, Speer CP. Chorioamnionitis is essential in the evolution of bronchopulmonary dysplasia--the case in favour. Paediatr Respir Rev. 2014;15:49–52.PubMed
6.
Kunzmann S, Collins JJP, Kuypers E, Kramer BW. Thrown off balance: The effect of antenatal inflammation on the developing lung and immune system. Am J Obstet Gynecol. 2013;208:429-37.
7.
Speer CP. Chorioamnionitis, postnatal factors and proinflammatory response in the pathogenetic sequence of bronchopulmonary dysplasia. Neonatology. 2009;95:353–61.CrossRefPubMed
8.
Glaser K, Speer CP. Toll-like receptor signaling in neonatal sepsis and inflammation: a matter of orchestration and conditioning. Expert Rev Clin Immunol. 2013;9:1239–52.CrossRefPubMed
9.
10.
Chen S, Rong M, Platteau A, Hehre D, Smith H, Ruiz P, Whitsett J, Bancalari E, Wu S. CTGF disrupts alveolarization and induces pulmonary hypertension in neonatal mice: implication in the pathogenesis of severe bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2011;300:L330–40.CrossRefPubMedPubMedCentral
11.
Shafieian M, Chen S, Wu S. Integrin-linked kinase mediates CTGF-induced epithelial to mesenchymal transition in alveolar type II epithelial cells. Pediatr Res. 2015;77:520–7.CrossRefPubMed
12.
Royce SG, Moodley Y, Samuel CS. Novel therapeutic strategies for lung disorders associated with airway remodelling and fibrosis. Pharmacol Ther. 2014;141:250–60.CrossRefPubMed
13.
14.
Cicha I, Goppelt-Struebe M. Connective tissue growth factor: context-dependent functions and mechanisms of regulation. Biofactors. 2009;35:200–8.CrossRefPubMed
15.
Leask A, Abraham DJ. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci. 2006;119:4803–10.CrossRefPubMed
16.
Ahmed MS, Oie E, Vinge LE, von Lueder TG, Attramadal T, Attramadal H. Induction of pulmonary connective tissue growth factor in heart failure is associated with pulmonary parenchymal and vascular remodeling. Cardiovasc Res. 2007;74:323–33.CrossRefPubMed
17.
18.
Halwani R, Al-Muhsen S, Al-Jahdali H, Hamid Q. Role of transforming growth factor-β in airway remodeling in asthma. Am J Respir Cell Mol Biol. 2011;44:127–33.CrossRefPubMed
19.
Pan LH, Yamauchi K, Uzuki M, Nakanishi T, Takigawa M, Inoue H, Sawai T. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J. 2001;17:1220–7.CrossRefPubMed
20.
Alapati D, Rong M, Chen S, Hehre D, Rodriguez MM, Lipson KE, Wu S: CTGF Antibody Therapy Attenuates Hyperoxia-Induced Lung Injury in Neonatal Rats. Am J Respir Cell Mol Biol. 2011;45(6):1169–77.
21.
Alapati D, Rong M, Chen S, Hehre D, Rodriguez MM, Lipson KE, Wu S. Connective tissue growth factor antibody therapy attenuates hyperoxia-induced lung injury in neonatal rats. Am J Respir Cell Mol Biol. 2011;45:1169–77.CrossRefPubMed
22.
Kunzmann S, Speer CP, Jobe AH, Kramer BW. Antenatal inflammation induced TGF-beta1 but suppressed CTGF in preterm lungs. Am J Physiol Lung Cell Mol Physiol. 2007;292:L223–31.CrossRefPubMed
23.
Grotendorst GR, Okochi H, Hayashi N. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ. 1996;7:469–80.PubMed
24.
Leask A, Parapuram SK, Shi-Wen X, Abraham DJ. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal. 2009;3:89–94.CrossRefPubMedPubMedCentral
25.
Laug R, Fehrholz M, Schütze N, Kramer BW, Krump-Konvalinkova V, Speer CP, Kunzmann S. IFN-γ and TNF-α synergize to inhibit CTGF expression in human lung endothelial cells. PLoS One. 2012;7:e45430.CrossRefPubMedPubMedCentral
26.
Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012;5:S24.CrossRefPubMedPubMedCentral
27.
Kubota S, Takigawa M. Cellular and molecular actions of CCN2/CTGF and its role under physiological and pathological conditions. Clin Sci (Lond). 2015;128:181–96.CrossRef
28.
29.
Bartram U, Speer CP. The role of transforming growth factor beta in lung development and disease. Chest. 2004;125:754–65.CrossRefPubMed
30.
Alejandre-Alcazar MA, Michiels-Corsten M, Vicencio AG, Reiss I, Ryu J, de Krijger RR, Haddad GG, Tibboel D, Seeger W, Eickelberg O, Morty RE. TGF-beta signaling is dynamically regulated during the alveolarization of rodent and human lungs. Dev Dyn. 2008;237:259–69.CrossRefPubMed
31.
Collins JJP, Kunzmann S, Kuypers E, Kemp MW, Speer CP, Newnham JP, Kallapur SG, Jobe AH, Kramer BW. Antenatal glucocorticoids counteract LPS changes in TGF-β pathway and caveolin-1 in ovine fetal lung. Am J Physiol Lung Cell Mol Physiol. 2013;304:L438–44.CrossRefPubMedPubMedCentral
32.
Kunzmann S, Collins JJP, Yang Y, Uhlig S, Kallapur SG, Speer CP, Jobe AH, Kramer BW. Antenatal inflammation reduces expression of caveolin-1 and influences multiple signaling pathways in preterm fetal lungs. Am J Respir Cell Mol Biol. 2011;45:969–76.CrossRefPubMedPubMedCentral
33.
Yeh TF, Chen CM, Wu SY, Husan Z, Li TC, Hsieh WS, Tsai CH, Lin HC. Intratracheal administration of Budesonide/Surfactant to prevent bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2016;193:86–95.CrossRefPubMed
34.
Rostas SE, McPherson C. Systemic corticosteroids for the prevention of bronchopulmonary dysplasia: picking the right drug for the right baby. Neonatal Netw. 2016;35:234–9.CrossRefPubMed
35.
Bancalari E, Claure N. Strategies to accelerate weaning from respiratory support. Early Hum Dev. 2013;89:70002–1.CrossRef
36.
Perretti M, D’Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol. 2009;9:62–70.CrossRefPubMed
37.
Ward C, Walters H. Airway wall remodelling: the influence of corticosteroids. Curr Opin Allergy Clin Immunol. 2005;5:43–8.CrossRefPubMed
38.
Gulliver T, Morton R, Eid N. Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. Paediatr Drugs. 2007;9:185–94.CrossRefPubMed
39.
Lista G, Fabbri L, Polackova R, Kiechl-Kohlendorfer U, Papagaroufalis K, Saenz P, Ferrari F, Lasagna G, Carnielli VP. The real-world routine use of caffeine citrate in preterm infants: a european postauthorization safety study. Neonatology. 2016;109:221–7.CrossRefPubMed
40.
Kreutzer K, Bassler D. Caffeine for apnea of prematurity: a neonatal success story. Neonatology. 2014;105:332–6.CrossRefPubMed
41.
Park HW, Lim G, Chung SH, Chung S, Kim KS, Kim SN. Early caffeine use in very Low birth weight infants and neonatal outcomes: a systematic review and meta-analysis. J Korean Med Sci. 2015;30:1828–35.CrossRefPubMedPubMedCentral
42.
Weichelt U, Cay R, Schmitz T, Strauss E, Sifringer M, Bührer C, Endesfelder S. Prevention of hyperoxia-mediated pulmonary inflammation in neonatal rats by caffeine. Eur Respir J. 2013;41:966–73.CrossRefPubMed
43.
Nagatomo T, Jimenez J, Richter J, De Baere S, Vanoirbeek J, Naulaers G, Allegaert K, Croubels S, Deprest JA, Toelen J. Caffeine prevents hyperoxia-induced functional and structural lung damage in preterm rabbits. Neonatology. 2016;109:274–81.CrossRefPubMed
44.
Köroğlu OA, MacFarlane PM, Balan KV, Zenebe WJ, Jafri A, Martin RJ, Kc P. Anti-inflammatory effect of caffeine is associated with improved lung function after lipopolysaccharide-induced amnionitis. Neonatology. 2014;106:235–40.CrossRefPubMedPubMedCentral
45.
Feld JJ, Lavoie ÉG, Fausther M, Dranoff JA. I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Res. 2015;4:95.PubMedPubMedCentral
46.
Tatler AL, Barnes J, Habgood A, Goodwin A, McAnulty RJ, Jenkins G: Caffeine inhibits TGFβ activation in epithelial cells, interrupts fibroblast responses to TGFβ, and reduces established fibrosis in ex vivo precision-cut lung slices. Thorax. 2016;71(6):565–7.
47.
Fehrholz M, Speer CP, Kunzmann S. Caffeine and rolipram affect smad signalling and TGF-β1 stimulated CTGF and transgelin expression in lung epithelial cells. PLoS One. 2014;9:e97357.CrossRefPubMedPubMedCentral
48.
Fehrholz M, Bersani I, Kramer BW, Speer CP, Kunzmann S. Synergistic effect of caffeine and glucocorticoids on expression of surfactant protein B (SP-B) mRNA. PLoS One. 2012;7:e51575.CrossRefPubMedPubMedCentral
49.
Fehrholz M, Hütten M, Kramer BW, Speer CP, Kunzmann S. Amplification of steroid-mediated SP-B expression by physiological levels of caffeine. Am J Physiol Lung Cell Mol Physiol. 2014;306:L101–9.CrossRefPubMed
50.
Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc. 2005;2:334–9. discussion 340–331.CrossRefPubMed
51.
Ferre S. An update on the mechanisms of the psychostimulant effects of caffeine. J Neurochem. 2008;105:1067–79.CrossRefPubMed
52.
Fredholm B: Methylxanthines. Handb Exp Pharmacol 2011:vii-viii.
53.
Onatibia-Astibia A, Martinez-Pinilla E, Franco R. The potential of methylxanthine-based therapies in pediatric respiratory tract diseases. Respir Med. 2016;112:1–9.CrossRefPubMed
54.
Kunzmann S, Schmidt-Weber C, Zingg J-M, Azzi A, Kramer BW, Blaser K, Akdis CA, Speer CP. Connective tissue growth factor expression is regulated by histamine in lung fibroblasts: potential role of histamine in airway remodeling. J Allergy Clin Immunol. 2007;119:1398–407.CrossRefPubMed
55.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25:402–8.CrossRefPubMed
56.
Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol. 2002;21:473–82.CrossRefPubMed
57.
Dammeier J, Beer HD, Brauchle M, Werner S. Dexamethasone is a novel potent inducer of connective tissue growth factor expression. Implications for glucocorticoid therapy. J Biol Chem. 1998;273:18185–90.CrossRefPubMed
58.
Wickert L, Chatain N, Kruschinsky K, Gressner AM. Glucocorticoids activate TGF-beta induced PAI-1 and CTGF expression in rat hepatocytes. Comp Hepatol. 2007;6:5.CrossRefPubMedPubMedCentral
59.
Kubota S, Moritani NH, Kawaki H, Mimura H, Minato M, Takigawa M. Transcriptional induction of connective tissue growth factor/hypertrophic chondrocyte-specific 24 gene by dexamethasone in human chondrocytic cells. Bone. 2003;33:694–702.CrossRefPubMed
60.
Wang W, Morrison B, Galbaugh T, Jose CC, Kenney N, Cutler ML. Glucocorticoid induced expression of connective tissue growth factor contributes to lactogenic differentiation of mouse mammary epithelial cells. J Cell Physiol. 2008;214:38–46.CrossRefPubMed
61.
Gauer S, Segitz V, Goppelt-Struebe M. Aldosterone induces CTGF in mesangial cells by activation of the glucocorticoid receptor. Nephrol Dial Transplant. 2007;22:3154–9.CrossRefPubMed
62.
Okada H, Kikuta T, Inoue T, Kanno Y, Ban S, Sugaya T, Takigawa M, Suzuki H. Dexamethasone induces connective tissue growth factor expression in renal tubular epithelial cells in a mouse strain-specific manner. Am J Pathol. 2006;168:737–47.CrossRefPubMedPubMedCentral
63.
Pereira RC, Durant D, Canalis E. Transcriptional regulation of connective tissue growth factor by cortisol in osteoblasts. Am J Physiol Endocrinol Metab. 2000;279:E570–6.PubMed
64.
Bassler D. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia. Neonatology. 2015;107:358–9.CrossRefPubMed
65.
Bancalari E, Jain D, Jobe AH. Prevention of bronchopulmonary dysplasia: Are intratracheal steroids with surfactant a magic bullet? Am J Respir Crit Care Med. 2016;193:12–3.CrossRefPubMed
66.
Neubauer V, Junker D, Griesmaier E, Schocke M, Kiechl-Kohlendorfer U. Bronchopulmonary dysplasia is associated with delayed structural brain maturation in preterm infants. Neonatology. 2015;107:179–84.CrossRefPubMed
67.
Renault A, Patkai J, Dassieu G, El Ayoubi M, Canoui-Poitrine F, Durrmeyer X. Hydrocortisone use in ventilated extremely preterm infants decreased bronchopulmonary dysplasia with no effects on neurodevelopment after two years. Acta Paediatr. 2016;30:13487.
68.
Ter Wolbeek M, Kavelaars A, de Vries WB, Tersteeg-Kamperman M, Veen S, Kornelisse RF, van Weissenbruch M, Baerts W, Liem KD, van Bel F, Heijnen CJ. Neonatal glucocorticoid treatment: long-term effects on the hypothalamus-pituitary-adrenal axis, immune system, and problem behavior in 14–17 year old adolescents. Brain Behav Immun. 2015;45:128–38.CrossRefPubMed
69.
Barrette AM, Roberts JK, Chapin C, Egan EA, Segal MR, Oses-Prieto JA, Chand S, Burlingame AL, Ballard PL. Anti-inflammatory effects of budesonide in human fetal lung. Am J Respir Cell Mol Biol. 2016;9:9.
70.
Bassler D, Plavka R, Shinwell ES, Hallman M, Jarreau P-H, Carnielli V, den Anker JNV, Meisner C, Engel C, Schwab M, et al. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. N Engl J Med. 2015;373:1497–506.CrossRefPubMed
71.
Dobson NR, Patel RM, Smith PB, Kuehn DR, Clark J, Vyas-Read S, Herring A, Laughon MM, Carlton D, Hunt CE. Trends in Caffeine Use and Association between Clinical Outcomes and Timing of Therapy in Very Low Birth Weight Infants. J Pediatr. 2014;164(5):992–8.e3.
72.
Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W: Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354:2112–21.
73.
Colwell AS, Phan TT, Kong W, Longaker MT, Lorenz PH. Hypertrophic scar fibroblasts have increased connective tissue growth factor expression after transforming growth factor-beta stimulation. Plast Reconstr Surg. 2005;116:1387–90.CrossRefPubMed
74.
Ask K, Bonniaud P, Maass K, Eickelberg O, Margetts PJ, Warburton D, Groffen J, Gauldie J, Kolb M. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3. Int J Biochem Cell Biol. 2008;40:484–95.CrossRefPubMed
75.
Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci. 1995;108:985–1002.PubMed
76.
Kothapalli D, Hayashi N, Grotendorst GR. Inhibition of TGF-beta-stimulated CTGF gene expression and anchorage-independent growth by cAMP identifies a CTGF-dependent restriction point in the cell cycle. FASEB J. 1998;12:1151–61.PubMed
77.
Croisier H, Tan X, Chen J, Sneyd J, Sanderson MJ, Brook BS. Ryanodine receptor sensitization results in abnormal calcium signaling in airway smooth muscle cells. Am J Respir Cell Mol Biol. 2015;53:703–11.CrossRefPubMedPubMedCentral
78.
Jaggupilli A, Singh N, Upadhyaya J, Sikarwar AS, Arakawa M, Dakshinamurti S, Bhullar RP, Duan K, Chelikani P. Analysis of the expression of human bitter taste receptors in extraoral tissues. Mol Cell Biochem. 2016;23:016–2902.
79.
Probert L. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience. 2015;302:2–22.CrossRefPubMed
80.
Chavez-Valdez R, Ahlawat R, Wills-Karp M, Gauda EB: Mechanisms of modulation of cytokine release by human cord blood monocytes exposed to high concentrations of caffeine. Pediatr Res. 2016;80(1):101–9.
81.
Ritter M, Hohenberger K, Alter P, Herzum M, Tebbe J, Maisch M. Caffeine inhibits cytokine expression in lymphocytes. Cytokine. 2005;30:177–81.CrossRefPubMed
82.
Horrigan LA, Kelly JP, Connor TJ. Caffeine suppresses TNF-alpha production via activation of the cyclic AMP/protein kinase A pathway. Int Immunopharmacol. 2004;4:1409–17.CrossRefPubMed
83.
Leitman DC, Ribeiro RC, Mackow ER, Baxter JD, West BL. Identification of a tumor necrosis factor-responsive element in the tumor necrosis factor alpha gene. J Biol Chem. 1991;266:9343–6.PubMed
Metadata
Title
Caffeine modulates glucocorticoid-induced expression of CTGF in lung epithelial cells and fibroblasts
Authors
Markus Fehrholz
Kirsten Glaser
Christian P. Speer
Silvia Seidenspinner
Barbara Ottensmeier
Steffen Kunzmann
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2017
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-017-0535-8

Other articles of this Issue 1/2017

Respiratory Research 1/2017 Go to the issue

Review

Intersectin-1s deficiency in pulmonary pathogenesis

Research

Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients

Research

The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study

Research

Sirolimus alters lung pathology and viral load following influenza A virus infection

Research

Extracellular histones are clinically relevant mediators in the pathogenesis of acute respiratory distress syndrome

Letter to the Editor

Asthma-COPD overlap is not a homogeneous disorder: further supporting data
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits